Actionable news
0
All posts from Actionable news
Actionable news in GILD: Gilead Sciences, Inc.,

Arrowhead Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2015

PASADENA, Calif.--(BUSINESS WIRE)--

Arrowhead Research Corporation (ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that additional clinical data on ARC-520, its RNAi therapeutic candidate for the treatment of chronic hepatitis B infection, will be presented in the late-breaking poster session at The Liver Meeting® 2015, the 66th Annual Meeting of the American Association for the Study of Liver Disease (AASLD)being held on November 13-17, 2015, in San Francisco.

The late-breaking abstract details results from the Heparc-2001, Phase 2 study of ARC-520 in combination with entecavir (ETV). Key findings include the following:

  • Naïve patients reduced viral DNA up to 4.3 log (mean 2.2 log)
  • Naïve e-antigen (HBeAg) positive patients reduced surface antigen (HBsAg) up to 1.9 log (mean max 1.1 log)
  • ARC-520 reduced HBeAg up to 1.7 log (mean max 1.2 log)
  • ARC-520 therapy was well tolerated with no adverse events rated serious, severe, drug-related or causing withdrawal from the trial
  • 15 patients are continuing in follow-up and additional results may be available to report at The Liver Meeting

Christopher Anzalone, Ph.D., president and CEO of Arrowhead, said, “In the Phase 2 study, ARC-520 effectively inhibited cccDNA-derived mRNA with protein knockdown up to 99% or 1.9 logs observed. This is the highest knockdown ever reported using RNAi in humans. Our clinical program and our study in chronically infected chimps continue to teach us a lot about HBV and we are thrilled to get the opportunity to make three presentations at The Liver Meeting next month.”

With the addition of the late-breaking poster, Arrowhead has the following three abstracts accepted for presentation at the Liver Meeting:

November 15, 3:15 p.m. PST – Christine Wooddell, Ph.D., group leader will deliver an oral presentation titled, “Reductions in cccDNA...


More